Limits...
A pilot study of omalizumab in eosinophilic esophagitis.

Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M, Gupta R, Balba N, Goker-Alpan O, Khojah A, Alpan O - PLoS ONE (2015)

Bottom Line: ClinicalTrials.gov NCT01040598.

View Article: PubMed Central - PubMed

Affiliation: Section on Immunopathogenesis, Food Allergy and Eosinophilic Disorders Program, O&O ALPAN, LLC, Fairfax, VA, United States of America; Amerimmune, Fairfax, VA, United States of America.

ABSTRACT

Trial registration: ClinicalTrials.gov NCT01040598.

No MeSH data available.


Comparison of blood AEC to symptom score.The x-axis represents symptoms scores before (left) and after (right) omalizumab, the y-axis represents AEC in peripheral blood.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4366078&req=5

pone.0113483.g008: Comparison of blood AEC to symptom score.The x-axis represents symptoms scores before (left) and after (right) omalizumab, the y-axis represents AEC in peripheral blood.

Mentions: Overall, changes in tissue eosinophil counts did not correlate with any changes in blood AECs (p = 0.5814, Table 3). When patients were stratified based on AEC count at baseline, there was a statistically significant correlation in patients with AEC < 450 (low-Eos) and histological response to omalizumab (p = 0.02). (Tables 2 and 3 and Fig. 7). Due to unequal number of subjects in high and low-eos groups, we were not able to perform a Wilcoxon signed-rank test, but compared the two groups by students t-test. When we compared the change in clinical symptom scores to changes in AEC, we found no correlation (Fig. 8, Table 4). In a recent study which included atopic asthmatics with elevated serum total IgE levels, high peripheral blood AEC was found to be a potential biomarker for assessing successful omalizumab treatment effects, which is in contrast to what we see in eosinophilic esophagitis [40]. In a study of omalizumab in patients with EGIDs [19], almost all patients had elevated blood eosinophil counts (> 500 per mm3at baseline) which may explain why histological improvements were not accompanied by clinical remission of disease. We see this contrast between histological responses to omalizumab in subjects with low versus high AEC (Fig. 7).


A pilot study of omalizumab in eosinophilic esophagitis.

Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M, Gupta R, Balba N, Goker-Alpan O, Khojah A, Alpan O - PLoS ONE (2015)

Comparison of blood AEC to symptom score.The x-axis represents symptoms scores before (left) and after (right) omalizumab, the y-axis represents AEC in peripheral blood.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4366078&req=5

pone.0113483.g008: Comparison of blood AEC to symptom score.The x-axis represents symptoms scores before (left) and after (right) omalizumab, the y-axis represents AEC in peripheral blood.
Mentions: Overall, changes in tissue eosinophil counts did not correlate with any changes in blood AECs (p = 0.5814, Table 3). When patients were stratified based on AEC count at baseline, there was a statistically significant correlation in patients with AEC < 450 (low-Eos) and histological response to omalizumab (p = 0.02). (Tables 2 and 3 and Fig. 7). Due to unequal number of subjects in high and low-eos groups, we were not able to perform a Wilcoxon signed-rank test, but compared the two groups by students t-test. When we compared the change in clinical symptom scores to changes in AEC, we found no correlation (Fig. 8, Table 4). In a recent study which included atopic asthmatics with elevated serum total IgE levels, high peripheral blood AEC was found to be a potential biomarker for assessing successful omalizumab treatment effects, which is in contrast to what we see in eosinophilic esophagitis [40]. In a study of omalizumab in patients with EGIDs [19], almost all patients had elevated blood eosinophil counts (> 500 per mm3at baseline) which may explain why histological improvements were not accompanied by clinical remission of disease. We see this contrast between histological responses to omalizumab in subjects with low versus high AEC (Fig. 7).

Bottom Line: ClinicalTrials.gov NCT01040598.

View Article: PubMed Central - PubMed

Affiliation: Section on Immunopathogenesis, Food Allergy and Eosinophilic Disorders Program, O&O ALPAN, LLC, Fairfax, VA, United States of America; Amerimmune, Fairfax, VA, United States of America.

ABSTRACT

Trial registration: ClinicalTrials.gov NCT01040598.

No MeSH data available.